Genetic Mutations that Lead to Chronic Myelogenous Leukemia: Causes and Treatments Marty O’Neill II & Carmen Banea

Slides:



Advertisements
Similar presentations
Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.
Advertisements

The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
Acute Myelogenous Leukemia and its Impact on the Immune System
I’ve just been diagnosed with CML. Could you answer my questions?
CLL- Chronic Lymphocytic Leukemia
Molecular Medicine. Focus on Cancer Most chemotherapies were developed before the human genome was sequenced Many are alkylating agents that attach methyl.
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
Leukemia By Mary Chen and Genesis Pimentel
Health Effects of Radiation
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Childhood Cancer Gabby Kulikowski & Kellie Campbell.
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.
LEUKEMIA. What Is It? Leukemia is a type of cancer that starts in the tissue that forms blood.
Chapter 17 Chronic Leukemias.
Marty O’Neill II Carmen Banea
Chronic Myeloid Leukemia Leukemia ALL, AML, CLL ALL, AML, CLL Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia –Cancer of the granulocytes or.
Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M. Kantarjian, MD Chairman; Professor, Department of Leukemia.
Lecture #3 The Cell Cycle & Cancer
Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.
Cancer.
Sami Sasala Brooke McVay Tiffany Vandiver

Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
Here are some CML slides that may be helpful for your presentation.
Which has the Human Genome Project most improved in the field of medicine? A. the ability to generate vaccines B. the diagnosis and treatment of disease.
10.3 Regulation.
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
The Future of Cancer and Treatments Abby Bridge AP Biology Period 1.
BIOL 445 – CANCER BIOLOGY PRESENTATION
Interesting Developments. Historic trends in biotech fields.
Chronic Myelogenous Leukemia By: Bobby Orr Danielle Heinbaugh Adam Edwards.
Cancer When cell division goes wrong……. Growing out of control, cancer cells produce malignant tumors Cancer is a general term for many diseases in.
Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.
Current use of imatinib in the treatment of chronic myeloid leukaemia Michael O’Dwyer Haematologica March 2003.
An Introduction to Cancer. Review of the Cell Cycle Using the flashcards, indicate the part of the cell cycle where each of the following activities occurs.
Notes - Cancer and Cell Division
Trends in Biotechnology Revision Questions. In 2005, ES-like cells were generated using four factors. The resulting cells were called iPS cells. What.
Leukemia By: Gabie Gomez. What is Leukemia? Blood consists of plasma and three types of cells, each type has a special function. RBC, WBC and Platelets.
Chronic myeloid leukaemia Cancer of granulocyte production Too many (non functioning) granulocytes are produced Bone marrow is overcrowded with ineffective.
Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…
Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.
Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.
By: Ashlynn Hill. Patrice Thompson  3 year who is battling leukemia.  The doctors suggest a bone marrow transplants for a long term survival.  Neither.
Polycythemia Vera (P.V.) By: Jake K. Period 2.
ONCOGENE AND ITS ROLE IN THE DEVELOPMENT OF LEUKAEMIA Nouf khaled al-Hajjar SUPERVISOR Dr.SAMINA HAQ.
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
Paige Myers & Mahek Shah.  Cancer is a disease in which the DNA of cells becomes damaged or changed and the affected cells do not respond to apoptosis.
GENETIC BIOMARKERS.
Drug Discovery &Development
Regulation of Cell Division and Cancer
CHRONIC MYELOID LEUKEMIA (CML)
The Eukaryotic Cell Cycle
Lecture #3 The Cell Cycle & Cancer
Cancer.
Lecture #4 The Cell Cycle & Cancer
Adaptive Response to Low Dose Radiation
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Stem Cells and Cellular Differentiation
Health Effects of Radiation
Neoplastic disorder.
Leukemia By: Fabiola Dominguez.
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
Objectives: 1. Cancer and the cell cycle checkpoints, reqmts to advance oncogenes tumor suppressor genes 2. 6 Traits of cancerous cells 3. Facts on.
Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova
Attacking Cancer at Its Root
The Pathway to Progress Against Chronic Myelogenous Leukemia.
Presentation transcript:

Genetic Mutations that Lead to Chronic Myelogenous Leukemia: Causes and Treatments Marty O’Neill II & Carmen Banea Introduction Throughout our research we discovered various articles which linked potential carcinogenic substances (e.g. benzene) to the development of mutations in humans leading to various types of leukemias. Some of the articles dated back to 1981 [7], yet little action has taken place to adequately prevent human exposure to these harmful substances. In the case of benzene, the maximum legal exposure level is dangerously close to the concentration level which has been found to cause genetic mutations in humans. The patient in the case study was exposed to benzene while working in a copy center for 5 years. During this period it is likely that the patient suffered the mutation that ultimately triggered CML, since the diagnosis followed shortly thereafter. Despite the fact that employers are advised that employees might be exposed to carcinogenic substances while working in a certain environment, few of them respond appropriately. Therefore stricter regulations should be enforced by the government, in particular OSHA, to ensure that employees are adequately protected. Development of STI-571 opens the door to the further development of anticancer agents which are designed to target specific molecular abnormalities in human cancer. Before development of this drug, chemotherapy was a common option used by healthcare practitioners for treating CML. Chronic stage patients are no longer restricted to following the harsh treatment of chemotherapy including prolonged hospital stays, intravenous injections, and severe side effects. Despite progress in CML treatment, many of the patients experience resistance to STI-571 either from the beginning or throughout the course of their treatment. New research is needed to discover how to counteract the resistance. Several new drugs are currently in phase three clinical trials (conducted by the FDA) that may prove to be more effective for treating patients with resistance to STI-571. Throughout our research we found that interest was focused on the shortened 22 nd chromosome abnormality, yet nothing was mentioned regarding the elongated 9 th. It would be interesting to find out whether further mutations are induced by the elongated 9 th chromosome, and what genes are potentially at risk. [1] D’Antonio, J. Chronic Myelogenous Leukemia. Clinical Journal of Oncology Nursing. 9(5): [2] Faderl et al. Oncology (Huntingt). 1999; 13:169. [3] Genetic Science Learning Center at the University of Utah. [4] National Marrow Donor Program overview slide presentation. [5] Medline Plus Medical Encyclopedia. [6] Pasternak et al. Chronic Meylogenous Leukemia: Molecular and Cellular Aspects. J Cancer Res Clin Oncol. 1998; [7] Rinsky et al. Leukemia in Benzene Workers. Am J Ind Med. 1981; 2(3): [8] Smith, MT & Zhang, L. Biomarkers of Leukemia Risk: Benzene as a Model. Environ Health Perspect Aug; 106 Suppl 4: [9] STI-571 in Chronic Myelogenous Leukaemia. British Journal of Haematology. 2002; Discussion Treatments References Causes Chronic Myelogenous Leukemia (CML) is defined as, “a malignant cancer of the bone marrow. It causes rapid growth of the blood-forming cells (known as myeloid precursors) in the bone marrow, peripheral blood, and body tissues.” [2] CML represents about 14% of all occurrences of leukemias. Patients who have CML are said to be in one of the following three phases (in order of occurrence): the chronic phase (between 1 and 15% blasts), the accelerated phase (between 15% - 30% blasts), and the blast phase (more than 30% blasts). [5] The chronic phase is the initial phase and the phase in which patients are most often diagnosed with CML [1]. The accelerated and blast phases are subsequent phases that represent further progression of CML in the patient and decreased chances of survival after treatment. Research concerning CML started in the XIX Century and is still in progress. There have been many important discoveries concerning CML regarding its causes, methods of detection in patients, treatments, and possible vaccines. Knowledge of Chronic Myelogenous Leukemia can be dated back to the mid-1800’s when symptoms of CML were first documented by Velpeau. Research continued, and about 20 years later, a high concentration of white blood cells in patients with CML was discovered. The term myelogenous was coined by Neuman after his 1878 discovery that bone marrow may not be the only place where blood cells were formed. In 1960, two scientists who lived in Philadelphia, Pennsylvania discovered what would later be called the Philadelphia (Ph) Chromosome: a direct indication of CML. The Philadelphia Chromosome results from a reciprocal translocation of parts of chromosomes 9 and 22 as is shown in Figure 1. This results in a shortened chromosome 22 called the Philadelphia Chromosome. Background The Philadelphia Chromosome FUSION PROTEIN WITH CONSTITUTIVE TYROSINE KINASE ACTIVITY bcr-abl bcr Philadelphia Chromosome (or 22q-) Chromosome 9 q+ abl Chromosome 9 Chromosome 22 Fig. 1 The Philadelphia Chromosome is a shortened chromosome 22 resulting from a translocation between chromosomes 9 and 22. [6] Pasternak et al. J Cancer Res Clin Oncol. 1998;124:643. Fig. 2 Survival probabilities of patients in Chronic Phase CML, following α-Interferon failure. The probability of survival for those treated with Imatinib Mesylate is significantly higher than those who were not treated with it. Imatinib information is only available for the past 4 years (since its release). National Marrow Donor Program overview slide presentation. [4] Accelerated and second chronic phase (n=744) Case Study Fig. 4 White Blood Count progression in subject beginning one year before being diagnosed, and continuing throughout the first year of treatment with STI-571. The patient was diagnosed with CML on December 21, The patient had a white blood count (WBC) performed in February, 2004, however, doctors did not conduct further tests despite anomalous WBC levels and distribution. Therefore, no additional tests were performed between February 2004 and December This is reflected in Figure 3 as a linear growth between these dates, despite the fact that it is likely that this growth would have been exponential due to normal cell division patterns. On December 15, 2004, the patient was found to have an enlarged spleen and had 4% blasts and 71,900 WBC, which indicated a potential diagnosis for CML. After bone marrow tests, the patient tested positive for BCR-ABL expression (resulting from Ph+-chromosome) which is a clear indication of CML. Genetic mutations occur due to DNA damage caused by external agents such as ultraviolet light, nuclear radiation, or certain chemicals. [3] Mutations may also occur during the process of copying DNA in preparation for cell division. Even such common occurrences as exposure to benzene (produced by photocopy machines), in concentrations not greatly above the current legal standard [7], may ultimately lead to genetic mutations that trigger diseases such as CML. [6] There are four principal therapeutic options which are mainly classified as: chemo therapy (hydroxyurea and busulfan), interferon, imatinib, and transplantation. While only transplantation usually leads to complete recovery, its drawbacks include a high risk of upfront mortality and limited availability depending on donor compatibility. [9] One of the newest discoveries in the field of cancer treatment is the development of STI-571 (Imatinib Mesylate), a milestone in modern pharmacology because of its ability to target specific molecules within cells (rational drug design). It was designed to bind to the Bcr-Abl tyrosine kinase molecule to impede its binding to the ATP (Adenosine 5’-triphosphate) molecule which would otherwise signal the leukemic cell to reproduce. This causes the leukemic cells to eventually die out by apoptosy. P PPP ATP Imatinib mesylate Bcr-Abl Blocked Fig. 3 Imatinib Mesylate binds to the Bcr-Abl kinase, blocking the ATP molecule from binding. Since the reaction between Bcr-Abl and ATP cannot occur, the cell never receives the signal to continue multiplying. This causes the apoptosy of the leukemic cell Months Survival probability TotalDead Imatinib mesylate Others (P<0.0001)